Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Tables)

v3.21.2
Significant Transactions (Tables)
9 Months Ended
Sep. 30, 2021
Business Acquisition [Line Items]  
Schedule of financial information combined results of operations



 Nine Months Ended
September 30,




2021
Revenue $ 15,064,163
Net loss $ (14,114,608 )


 Three Months Ended
September 30,




2020
Revenue $ 4,986,671
Net loss $ (3,365,226 )



Nine Months Ended
 September 30,



2020
Revenue $ 16,348,997
Net loss $ (18,014,765 )


Viridian Sciences [Member]  
Business Acquisition [Line Items]  
Schedule of estimated acquisition date fair value of consideration

 

 

Preliminary
Fair Value

 

Shares issued

 

$

6,000

 

Contingent consideration

2
Total preliminary fair value of consideration transferred
$ 6,002
Schedule of preliminary estimated fair values of assets acquired and liabilities

 

 

Preliminary
Fair Value

 

Accounts receivable

 

 

556

 

Prepaid expenses and other current assets

 

 

148

 

Capitalized software

423

Acquired technology

 

 

470

 

Customer relationships

820
Acquired trade name

20
Goodwill

4,915

Accounts payable and accrued expenses

 

 

(350

)

Deferred revenue

 

 

(1,000

)

Net assets acquired

 

$

6,002